Targeting the MUC1 cytoplasmic domain (MUC1-C) genetically or pharmacologically decreased: (i) expression of breast cancer stem cell markers including SOX2 (Hata et al., 2019); and (ii) lung cancer stem cell generation associated with decreased levels of SOX2 (Ham et al., 2016). The gene discussed is SOX2; the disease is lung carcinoma.